Literature DB >> 869985

Growth kinetics of Kaposi's sacroma.

J F Taylor, O H Iversen, R Bjerknes.   

Abstract

This is a study of cell kinetics in nodular and florid (fungating) Kaposi's sarcomas. One or more tumours from 9 patients were examined at the Uganda Cancer Institute. The very variable clinical doubling time was assessed by direct measurements of tumour diameters, and an average obtained. The mitotic count, rate of entry of cells into mitosis and cell cycle time were measured in biopsy material, and use to estimate the potential doubling time. From the difference between the potential and the actual doubling times, the rate of cell loss and the cell loss factor were calculated. The average actual clinical doubling time was slightly, but not significantly, higher for growing nodular tumours than for florid tumours. Some nodular tumours were similar to those reported in the literature for other human malignacies. Kinetic studies of static and regressing human tumours have not been reported previously. The rate of cell production found in this tumour is lower than the values reported in the literature for other malignancies. The calculated mitotic duration is long, but similar to previously reported values. The cell loss factor is high: in the static tumours it is 1.0, and in the regressing tumours greater than 1.0. In regressing tumours, the rate of cell loss was 30% higher than the rate of cell production. These tumours did not differ histologically from nearly florid tumours which were increasing in size. It is postulated that regression is determined by local vascular or mechanical factors, supplemented possibly by delayed hypersensitivity responses in some patients.

Entities:  

Mesh:

Year:  1977        PMID: 869985      PMCID: PMC2025337          DOI: 10.1038/bjc.1977.70

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  13 in total

1.  Relation between the pathological nature and the growth rate of human tumors.

Authors:  A Charbit; E P Malaise; M Tubiana
Journal:  Eur J Cancer       Date:  1971-08       Impact factor: 9.162

2.  Exponential growth.

Authors:  R Bjerknes
Journal:  Eur J Cancer       Date:  1974-03       Impact factor: 9.162

3.  Cell production in tumour isografts measured using vincristine and Colcemid.

Authors:  S R Smith; D B Thomas; A C Riches
Journal:  Cell Tissue Kinet       Date:  1974-11

4.  Kaposi's sarcoma in Uganda: a clinico-pathological study.

Authors:  J F Taylor; A C Templeton; C L Vogel; J L Ziegler; S K Kyalwazi
Journal:  Int J Cancer       Date:  1971-07-15       Impact factor: 7.396

5.  Treatment of Kaposi's sarcoma with actinomycin-D and cyclophosphamide: results of a randomized clinical trial.

Authors:  C L Vogel; C J Templeton; A C Templeton; J F Taylor; S K Kyalwazi
Journal:  Int J Cancer       Date:  1971-07-15       Impact factor: 7.396

6.  Lymphocyte transformation in patients with Kaposi's sarcoma.

Authors:  J F Taylor; U Junge; L Wolff; F Deinhardt; S K Kyalwazi
Journal:  Int J Cancer       Date:  1971-11-15       Impact factor: 7.396

7.  Vasoactive substances in Kaposi's sarcoma.

Authors:  D Bhana; K Hillier; S M Karim
Journal:  Cancer       Date:  1971-01       Impact factor: 6.860

8.  Kaposi sarcoma and Burkitt's lymphoma.

Authors:  B McKinney
Journal:  East Afr Med J       Date:  1967-10

9.  Demecolcin and vinblastine sulphate as stathmokinetic agents for different tissues of the hairless mouse.

Authors:  O Nome
Journal:  Pathol Eur       Date:  1975

10.  Delayed cutaneous hypersensitivity reactions in patients with Kaposi's sarcoma.

Authors:  J F Taylor; J L Ziegler
Journal:  Br J Cancer       Date:  1974-10       Impact factor: 7.640

View more
  1 in total

1.  Disentangling Kaposi's sarcoma.

Authors: 
Journal:  Br Med J       Date:  1978-10-14
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.